UK MHRA Extends Deadline for Annual Medical Device Registration Fees to 31 July 2026

Source

• Source organisation: MHRA / GOV.UK
• Original date: 1 July 2026
• Published by AIMEILI: 8 July 2026, 09:00
• Original link: https://www.gov.uk/guidance/register-medical-devices-to-place-on-the-market

According to the GOV.UK guidance on registering medical devices, the MHRA has extended the deadline for the payment of annual registration fees to 31 July 2026, reminding companies to review their UK registration accounts, fee structure and the responsibilities of the UK Responsible Person.

Full Translation of the Core Content

The GOV.UK guidance on registering medical devices states that the MHRA has extended the deadline for paying annual fees to 31 July 2026, so that the companies concerned can adapt to the new fee structure and confirm the medical devices they have registered.

The same page explains that manufacturers placing medical devices on the UK market are generally required to register with the MHRA. Where the manufacturer is not established in the UK, a UK Responsible Person must be appointed to act on its behalf in discharging the relevant responsibilities.

UK medical device registration is not a one-off submission that can then be left unattended over the long term. Companies must maintain their MHRA account, the list of registered products, annual fees, UK Responsible Person information, labelling content, certificate validity and post-market communication mechanisms on an ongoing basis. If registration information, fees or the local responsible entity are not properly maintained, the continued supply of the product to the UK market may be affected.

Companies already selling in the UK, or preparing to enter the UK market, should manage annual fees, the scope of product registration, UK Responsible Person arrangements, the UKCA/CE transition period and post-market surveillance requirements within a single tracking register.

Business Impact

UK registration is not a one-off submission that can then be left unattended. Companies need to monitor their MHRA account, registered product list, annual fees, UK Responsible Person, labelling information, certificate validity and post-market communication. If annual fees, the UKRP arrangement or registration information are not properly maintained, the continued supply of the product to the UK market may be affected.

AIMEILI Regulatory Interpretation

AIMEILI's regulatory team considers that updates of this kind remind companies that national registration is not simply about obtaining a certificate for the first time. It also involves long-term management of accounts, fees, the local responsible entity, business licences, annual maintenance, changes and post-market communication. Mature markets such as Canada and the UK place particular emphasis on a local compliance entity, continuously accurate registration information, fee payment and a closed loop of regulatory communication.

For Chinese manufacturers, before entering these markets it is important to distinguish between the product licence, the business licence, importer/distributor responsibilities, and the responsibilities of the UK Responsible Person or the local Canadian sales chain. Many companies focus only on technical documentation at the time of the initial submission and overlook who will maintain the account afterwards, who will receive regulatory notifications, who will handle complaints and recalls, and how certificates and documentation will be transferred if the distribution channel changes. If these issues are not properly designed at the outset, later changes in commercial arrangements can directly affect continued product sales.

AIMEILI recommends that companies establish a certificate maintenance register for each target country, covering the registration holder, certificate validity, annual fees, local representative, importer, distributor, change notifications, label versions, complaint contact and renewal milestones. For B2B companies expanding overseas, certificate maintenance capability and market control are equally important; all compliance access points should not be handed over to a single channel partner without an exit mechanism.

Recommended Compliance Actions

• Confirm whether this update affects existing registration pathways, certificate maintenance or post-market obligations.
• Verify the technical documentation, labelling and instructions for use, quality system and local responsible entity arrangements for the target country.
• Establish change impact assessments and regulatory update tracking records for products already on the market.
• Where necessary, archive the official source text, the English-language interpretation and internal action items to support future audits and project reviews.

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the regulatory authority in the target country, testing conclusions or legal advice.